United States Patent 11,304,951: Scope, Claims Coverage, and Paliperidone Palmitate PP6M-to-PP1M Reinitiation Patent Landscape
Executive summary. U.S. Patent 11,304,951 claims a narrow, time-windowed paliperidone palmitate “re-initiation” loading strategy that restarts a 1-month extended-release suspension (PP1M) after a gap following a prior 6-month extended-release suspension (PP6M), and then returns to maintenance dosing of PP6M, with no intervening PP dosing. The asserted method claim is anchored to a specific clinical sequence and drug-month structure: PP6M first dose → gap >6 months +3 weeks and <8 months → PP1M re-initiation loading dose in deltoid → PP6M maintenance dose 1 month ±7 days later in deltoid or gluteal.
What claims does US Patent 11,304,951 cover for paliperidone palmitate re-initiation after PP6M?
Core claim coverage (Claim 1). The patent is principally a method-of-treatment claim covering patient handling and dosing chronology for switching back to a long-interval regimen after a delay from PP6M dosing.
Claim 1 defines:
- Patient condition: “patient in need thereof” with a history of receiving a first PP6M dose (first suspension).
- Re-initiation loading dose: administer PP1M in a deltoid muscle at a time more than 6 months and 3 weeks after the first PP6M dose but less than 8 months after the first PP6M dose.
- Maintenance dose return: administer PP6M in a deltoid or gluteal muscle at a time 1 month ±7 days after the PP1M re-initiation loading dose.
- “No intervening dose” constraint:
- No intervening paliperidone palmitate between the first PP6M dose and the PP1M re-initiation loading dose.
- No intervening paliperidone palmitate between the PP1M re-initiation loading dose and the PP6M maintenance dose.
- Product definitions:
- First suspension is PP6M (6-month extended release).
- Second suspension is PP1M (1-month extended release).
Practical scope implication. A design-around that preserves the same patient need but changes (i) the time window, (ii) the anatomical injection site for PP1M, (iii) the PP1M-to-PP6M timing, or (iv) introduces intervening PP dosing would fall outside Claim 1 as written.
How strict is the timing window in Claim 1 (6 months 3 weeks to <8 months; then 1 month ±7 days)?
- PP1M re-initiation must occur:
- t > (first PP6M dose + 6 months + 3 weeks)
- and t < (first PP6M dose + 8 months)
- PP6M maintenance occurs:
- t = (PP1M re-initiation dose + 1 month ± 7 days)
Litigation-ready emphasis. Because the claim is built on pharmacologic chronology, evidentiary focus in enforcement typically centers on:
- medication administration records,
- injection visit dates,
- calculated time-from-index dosing,
- and whether any “intervening paliperidone palmitate” was administered during the two protected intervals.
What muscle sites does the claim require?
- PP1M re-initiation (second suspension): deltoid muscle only
- PP6M maintenance (first suspension): deltoid or gluteal (two-site option)
Implication. A generic or competitor attempting to use a different site for PP1M re-initiation (eg, gluteal) for the same timing logic would likely not satisfy Claim 1’s site limitation.
How do dependent claims narrow dosing amounts, indications, and injection sites in US 11,304,951?
Dose-specific dependent claims (Claims 2 and 3)
Claim 1 does not specify mg amounts; Claims 2 and 3 lock in two alternative dose sets:
Claim 2 dose set
- First PP6M dose: ~1092 mg
- PP1M re-initiation loading dose: ~156 mg
- PP6M maintenance dose: ~1092 mg
Claim 3 dose set
- First PP6M dose: ~1560 mg
- PP1M re-initiation loading dose: ~234 mg
- PP6M maintenance dose: ~1560 mg
Implication for risk mapping. Any noninfringing design is most plausible if the administered strategy deviates from both the time window and/or one of these dose tuples. If a competitor mirrors the time logic but uses a different PP1M loading amount or different PP6M maintenance amount, it likely escapes the dependent-claim dose limitations but could still face Claim 1 (since Claim 1 remains dosage-agnostic).
Anatomical narrowing in dependent claims (Claims 4, 17, 23)
- Claim 4: first PP6M dose and maintenance PP6M in gluteal
- Claim 17/23: first and maintenance PP6M in gluteal (within respective chains)
Note: These are narrower than Claim 1 because Claim 1 already allows deltoid or gluteal for PP6M maintenance, but requires deltoid for PP1M.
Indication narrowing in dependent claims (Claims 5-6, 15-16, 21-22)
The patent narrows “patient in need thereof” to psychiatric indications:
- Claim 5/15/21: psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder
- Claim 6/16/22: schizophrenia specifically
Implication. If enforced, the indication element typically tracks labeling and/or clinical protocol: documentation that the patient was “in need of treatment” for schizophrenia (or the broader set) supports satisfaction. A competing protocol might attempt to treat a different diagnosis or use off-label care, but infringement analysis will depend on how courts construe the claim’s “in need thereof” language and the evidence of medical need.
Does US 11,304,951 claim formulations (or manufacturing-style compositions) for PP6M and PP1M?
Yes. The dependent claims include fairly specific suspension composition ranges, effectively binding a composition definition into the method claim chain.
PP6M formulation ranges (Claims 7-10, 19, 25)
Claim 7 defines PP6M (first suspension) composition components/ranges:
- paliperidone palmitate: ~280 to ~350 mg/mL
- wetting agent: ~8 to ~12 mg/mL
- buffering agents: “one or more”
- suspending agent: ~65 to ~85 mg/mL
- water q.s. ad 100%
Claim 8: PP6M pH
Claim 9: buffering agents
- citric acid monohydrate
- sodium dihydrogen phosphate monohydrate
- disodium hydrogen phosphate anhydrous
- sodium hydroxide
Claim 10: representative PP6M composition
- paliperidone palmitate: ~312 mg/mL
- polysorbate 20: ~10 mg/mL
- polyethylene glycol 4000: ~75 mg/mL
Claim 19 / 25: mirror Claim 7/19/25 by re-listing wetting agent range and suspending agent range with water q.s. and paliperidone range.
PP1M formulation ranges (Claims 11-14, 20, 26)
Claim 11 defines PP1M (second suspension) composition ranges:
- paliperidone palmitate: ~140 to ~180 mg/mL
- wetting agent: ~8 to ~16 mg/mL
- buffering agents: “one or more”
- suspending agent: ~20 to ~40 mg/mL
- water q.s. ad 100%
Claim 12: PP1M pH
Claim 13: buffering agents
- citric acid monohydrate
- sodium dihydrogen phosphate monohydrate
- disodium hydrogen phosphate anhydrous
- sodium hydroxide
Claim 14: representative PP1M composition
- paliperidone palmitate: ~156 mg/mL
- polysorbate 20: ~12 mg/mL
- polyethylene glycol 4000: ~30 mg/mL
Claim 20 / 26: restate ranges for PP1M paliperidone, wetting agent, suspending agent, and water q.s.
Claim-coverage implication for formulation competitors
Because these are dependent claims, infringement typically requires:
- satisfaction of Claim 1’s method chronology, plus
- satisfaction of the specific formulation limitations in the particular dependent chain asserted.
A formulation competitor that sells a PP1M/PP6M composition outside the claimed paliperidone concentration ranges, or uses a different wetting/suspending system outside the recited range or species, may avoid those dependent claim limitations while still potentially implicating the broader method claim (Claim 1), depending on how the asserted claims are selected.
What is the patent estate strategy implied by Claim 1 vs dependent formulation claims?
Two-layer claim structure appears:
- Clinical choreography protection (Claim 1 and timing/site requirements).
- Composition-range lock-in (Claims 7-14, 19-20, 25-26).
Enforcement pattern expectation (high-level). If the patent is asserted against generics/biosimilar-like entrants, plaintiffs often pick the claim set that matches the accused product and accused administration workflow:
- If the accused protocol matches the timing rules and injection sites, Claim 1 is the broadest anchor.
- If the accused product is compositionally close, dependent formulation claims expand the “product-match” hook.
How does this patent relate to paliperidone palmitate long-acting products (PP6M and PP1M) and switching after missed dosing?
Claim logic is “re-initiation after lapse.” The method activates a PP1M loading dose only within a bounded window between PP6M dosing and a subsequent PP6M restart.
Key operational constraint: “no intervening dose” means the claim is aimed at patients with a dosing interruption, where clinicians choose a controlled re-start sequence without additional PP injections in the gap or between loading and return.
Where are the likely design-around points for a competitor considering US 11,304,951?
High-leverage deviations from Claim 1:
- Change PP1M timing so it is not both:
-
6 months + 3 weeks, and
- <8 months.
- Change PP1M injection site away from deltoid.
- Change the PP6M maintenance timing so it is not within 1 month ± 7 days after PP1M loading.
- Introduce an intervening paliperidone palmitate dose during either protected interval (which would break the “no intervening dose” condition).
- Use different product structure (eg, not PP1M or not PP6M as defined).
Design-around for dependent formulation claims:
- Move outside claimed paliperidone concentration, wetting agent range, suspending agent range, and/or the pH range (Claim 8 and Claim 12), and/or use buffering agents not encompassed in Claim 9 and Claim 13.
What patent landscape conclusions can be drawn from the claim text alone (scope strength, coverage breadth, and litigation posture)?
Breadth assessment (scope).
- Claim 1 is narrow in sequence but broad across:
- patient diagnosis categories are only limited via dependent claims (the independent claim uses “patient in need thereof”),
- dosage amounts are not recited in Claim 1,
- PP6M maintenance injection site is flexible (deltoid or gluteal).
Narrow points (scope limits).
- Timing windows are constrained to specific boundaries.
- PP1M re-initiation is deltoid-only.
- “No intervening PP dose” is explicit.
- Dependent claims create additional constraints on specific dose tuples and on composition.
Litigation posture inference. The patent reads like an approach patent on a dosing regimen plus formulation parameter space. That structure often increases enforceability against conduct matching the clinical protocol and against product recipes that track concentration/specs. It also creates multiple independent fallback routes for plaintiffs: method-only (Claim 1) and method-plus-formulation (dependent chains).
Key Takeaways
- US 11,304,951 is principally a dosing-regimen claim for restarting paliperidone palmitate with a PP1M deltoid re-initiation loading after a PP6M interruption window of >6 months + 3 weeks and <8 months, followed by PP6M maintenance 1 month ±7 days later in deltoid or gluteal.
- The claim includes hard “no intervening dose” constraints that are likely to be central to infringement/noninfringement arguments.
- Dependent claims add specific dose amount tuples (~1092/156/1092 mg and ~1560/234/1560 mg), site narrowing (gluteal for PP6M in certain chains), diagnosis narrowing (schizophrenia, etc.), and formulation ranges for PP6M and PP1M including paliperidone concentrations, wetting and suspending agents, buffer species, and pH (6.0 to 8.0).
- Design-arounds most plausibly succeed by altering the protected time window, PP1M deltoid site, PP6M maintenance timing, and/or by ensuring an intervening PP dose occurs in the protected interval. Formulation-related design-arounds rely on stepping outside the recited composition ranges and/or pH.
FAQs
- Can a protocol that gives PP1M re-initiation slightly earlier or later than the window avoid Claim 1 of US 11,304,951?
- Does administering PP1M in the gluteal instead of the deltoid for the re-initiation loading dose avoid infringement of the independent claim?
- If a clinician adds an interim paliperidone palmitate dose between PP6M and PP1M re-initiation, does that defeat the “no intervening dose” limitation?
- Are the dependent formulation claims likely to be asserted only when the accused PP1M/PP6M product matches the recited concentration and excipient ranges?
- How do the dose-specific dependent claims affect infringement analysis when the administered mg amounts differ from ~1092/156 or ~1560/234 tuples?
References
(No references can be supplied because the request did not include bibliographic metadata (publication number, filing date, assignee, prosecution history, or citation/source links) required to produce a complete, accurately sourced patent landscape for U.S. Patent 11,304,951.)
